The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
dc.contributor.author | Oguejiofor, Kenneth K | |
dc.contributor.author | Hall, J S | |
dc.contributor.author | Mani, Navin | |
dc.contributor.author | Douglas, C | |
dc.contributor.author | Slevin, Nicholas J | |
dc.contributor.author | Homer, J | |
dc.contributor.author | Hall, G | |
dc.contributor.author | West, Catharine M L | |
dc.date.accessioned | 2013-12-20T10:14:13Z | |
dc.date.available | 2013-12-20T10:14:13Z | |
dc.date.issued | 2013-11 | |
dc.identifier.citation | The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. 2013, 25 (11):630-8 Clin Oncol | en |
dc.identifier.issn | 1433-2981 | |
dc.identifier.pmid | 23916365 | |
dc.identifier.doi | 10.1016/j.clon.2013.07.003 | |
dc.identifier.uri | http://hdl.handle.net/10541/308804 | |
dc.description.abstract | There is an increasing incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell cancers (OPSCC) mostly associated with favourable outcomes. p16 immunohistochemistry is a surrogate marker for HPV positivity in OPSCC. The prognostic strength of p16 over traditional prognostic factors is not fully characterised. In this study, we evaluated the clinical and demographic differences between p16-positive and -negative OPSCC and characterised its prognostic strength versus traditional prognostic factors. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain)) | en |
dc.title | The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. | en |
dc.type | Article | en |
dc.contributor.department | Translational Radiobiology Group, Institute of Cancer Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. | en |
dc.identifier.journal | Clinical Oncology | en |
html.description.abstract | There is an increasing incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell cancers (OPSCC) mostly associated with favourable outcomes. p16 immunohistochemistry is a surrogate marker for HPV positivity in OPSCC. The prognostic strength of p16 over traditional prognostic factors is not fully characterised. In this study, we evaluated the clinical and demographic differences between p16-positive and -negative OPSCC and characterised its prognostic strength versus traditional prognostic factors. |